A review of the clinical use of anti-inflammatory therapies for reperfusion injury in myocardial infarction and stroke: Where do we go from here?

被引：0
作者：
Kennedy, TP
Vinten-Johansen, J
机构：
[1] Univ Utah, Med Ctr, Div Resp Crit Care & Occupat Pulm Med, Salt Lake City, UT 84132 USA
[2] Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30308 USA
[3] Emory Univ, Sch Med, Div Cardiothorac Surg, Atlanta, GA 30308 USA
来源：
CURRENT OPINION IN INVESTIGATIONAL DRUGS | 2006年 / 7卷 / 03期
关键词：
adenosine; anti-inflammatory; ischemia; myocardial infarction; reperfusion;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
A number of prominent studies have been conducted using anti-inflammatory therapies to reduce reperfusion injury in myocardial infarction and stroke. Unfortunately, most strategies have failed. This review summarizes in detail the human studies of anti-inflammatory therapy that have been conducted to date. The potential reasons for treatment failure will be discussed from a non-clinical perspective, as will lessons learned from these studies that might guide the design of future clinical studies in this important area.
引用
收藏
页码：229 / 242
页数：14
相关论文
共 120 条
[1]   A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction [J].
Antoniucci, D ;
Rodriguez, A ;
Hempel, A ;
Valenti, R ;
Migliorini, A ;
Vigo, F ;
Parodi, G ;
Fernandez-Pereira, C ;
Moschi, G ;
Bartorelli, A ;
Santoro, GM ;
Bolognese, L ;
Colombo, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (11) :1879-1885
[2]   Inhibition by heparin of protein kinase C activation and hydroxyl radical generation in puromycin aminonucleoside treated isolated rat hepatocytes [J].
Aoyagi, K ;
Kuzure, Y ;
Shahrzad, S ;
Hirayama, A ;
Nagase, S ;
Ueda, A .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2003, 244 (01) :3-9
[3]   Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention [J].
Armstrong, PW ;
Adams, PX ;
Al-Khalidi, HR ;
Hamm, C ;
Holmes, D ;
O'Neill, W ;
Todaro, TG ;
Vahanian, A ;
Van de Werf, F ;
Granger, CB .
AMERICAN HEART JOURNAL, 2005, 149 (03) :402-407
[4]   Protein kinase activation and myocardial ischemia/reperfusion injury [J].
Armstrong, SC .
CARDIOVASCULAR RESEARCH, 2004, 61 (03) :427-436
[5]  
Assali AR, 2000, CATHETER CARDIO INTE, V51, P27, DOI 10.1002/1522-726X(200009)51:1<27::AID-CCD7>3.0.CO
[6]  
2-0
[7]   Double-blind, randomized trial of an Anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction - Limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study [J].
Baran, KW ;
Nguyen, M ;
McKendall, GR ;
Lambrew, CT ;
Dykstra, G ;
Palmeri, ST ;
Gibbons, RJ ;
Borzak, S ;
Sobel, BE ;
Gourlay, SG ;
Rundle, AC ;
Gibson, CM ;
Barron, HV .
CIRCULATION, 2001, 104 (23) :2778-2783
[8]   The neutrophil as a mediator of myocardial ischemia-reperfusion injury: time to move on [J].
Baxter, GF .
BASIC RESEARCH IN CARDIOLOGY, 2002, 97 (04) :268-275
[9]  
Becker Kyra J, 2002, Curr Med Res Opin, V18 Suppl 2, ps18, DOI 10.1185/030079902125000688
[10]   New concepts in reactive oxygen species and cardiovascular reperfusion physiology [J].
Becker, LB .
CARDIOVASCULAR RESEARCH, 2004, 61 (03) :461-470
12345678910